The National Cancer Institute recognizes CytoFind™ as a powerful tool that enables real-time monitoring of circulating tumor cells (CTCs), allowing for accurate prediction of therapeutic responses. By matching patients with compatible therapies, the technology can mitigate side effects and adverse events.
News + Resources
News + Resources
A liquid biopsy for detecting circulating mesothelial precursor cells: A new biomarker for diagnosis and prognosis in mesothelioma
Malignant pleural mesothelioma (MPM) is an aggressive cancer related to asbestos exposure. Early diagnosis is challenging due to generic symptoms and a lack of biomarkers.
Tracking the expression of therapeutic protein targets in rare cells by antibody-mediated nanoparticle labelling and magnetic sorting
Molecular-level features of tumours can be tracked using single-cell analyses of circulating tumour cells (CTCs). However, single-cell measurements of protein expression for rare CTCs are hampered by the presence of a large number of non-target cells.
Circulating Tumor Cell Collection, Analysis Methods Make Headway in 2019
In a busy year for CTC capture and detection, several academic and commercial groups develop novel techniques. With growing interest in the technology, the US National Cancer Institute announces plans to fund research for integrating imaging and liquid biopsies. Cellular Analytics pushes forward with CytoFind™, allowing for real-time measurement of expressed surface proteins and mRNA content.
Ultrasensitive and rapid quantification of rare tumorigenic stem cells in hPSC-derived cardiomyocyte populations
The ability to detect rare human pluripotent stem cells (hPSCs) in differentiated populations is critical for safeguarding the clinical translation of cell therapy, as these undifferentiated cells have the capacity to form teratomas in vivo.
FACIT and University of Toronto launch precision medicine company: Cellular Analytics
FACIT, a commercialization venture group, backs Cellular Analytics in an initial seed funding round. Capital from FACIT’s Compass Rose Oncology Fund will be used to develop the non-invasive, commercial prototype of the CytoFind™ technology.